Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROCLAIM: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure

NCT00099580 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00099580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROCLAIM: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
September 30, 2006
Enrollment
61 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure